BioNTech SE (BNTX) Research & Development (2018 - 2025)
BioNTech SE (BNTX) posted Research & Development of -$588.3 million for Q4 2025, up 10.9% on a QoQ basis from -$660.3 million in Q3 2025, and up 10.01% year-over-year from -$534.8 million in Q4 2024.
BioNTech SE (BNTX) has 8 years of Research & Development data on file, last reported at -$588.3 million in Q4 2025.
- In Q4 2025, Research & Development rose 10.01% year-over-year to -$588.3 million; the TTM figure through Dec 2025 stood at -$2.4 billion (up 2.51% YoY), while the FY2025 annual figure was -$2.4 billion, up 1.27% from the prior year.
- Research & Development improved to -$588.3 million in Q4 2025, from -$660.3 million in the prior quarter.
- Across five years, Research & Development topped out at -$242.2 million in Q2 2021 and bottomed at -$660.3 million in Q3 2025.
- A 5-year average of -$473.9 million and a median of -$531.1 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2021 — Research & Development slumped 101360660.56% — and 2025, when it climbed 10.01%.
- Year by year, Research & Development stood at -$310.6 million in 2021, then tumbled by 67.46% to -$520.1 million in 2022, then retreated by 19.53% to -$621.7 million in 2023, then slipped by 5.16% to -$653.8 million in 2024, then increased by 10.01% to -$588.3 million in 2025.
- The last three Research & Development figures came in at -$588.3 million (Q4 2025), -$660.3 million (Q3 2025), and -$576.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | BioNTech SE | 27.66 Bn | 7.53 Bn | 668.28 Mn | -588.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -588.31 Mn |
| Sep 30, 2025 | -660.28 Mn |
| Jun 30, 2025 | -576.28 Mn |
| Mar 31, 2025 | -552.87 Mn |
| Dec 31, 2024 | -653.77 Mn |
| Sep 30, 2024 | -604.35 Mn |
| Jun 30, 2024 | -629.55 Mn |
| Mar 31, 2024 | -551.33 Mn |
| Dec 31, 2023 | -621.68 Mn |
| Sep 30, 2023 | -542.01 Mn |
| Jun 30, 2023 | -406.60 Mn |
| Mar 31, 2023 | -358.50 Mn |
| Dec 31, 2022 | -520.12 Mn |
| Sep 30, 2022 | -344.63 Mn |
| Jun 30, 2022 | -426.40 Mn |
| Mar 31, 2022 | -320.76 Mn |
| Dec 31, 2021 | -310.59 Mn |
| Sep 30, 2021 | -307.09 Mn |
| Jun 30, 2021 | -242.18 Mn |
| Mar 31, 2021 | -260.79 Mn |
| Dec 31, 2020 | -306.42 |
| Mar 31, 2020 | 7.29 Mn |
| Dec 31, 2019 | 428.96 Mn |
| Sep 30, 2019 | -56.08 Mn |
| Dec 31, 2018 | 103.98 Mn |
| Sep 30, 2018 | -38.14 Mn |